-
APEX2 Controls TERT Expression in Human Stem Cells
2026-08-18
This preprint identifies APEX2 as a DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma model. Integrated knockdown, RNA-seq, telomerase activity, and chromatin immunoprecipitation data suggest that APEX2 may support transcription through repair of damage-prone repetitive DNA near TERT, particularly MIR elements in intron 2.
-
AZD3463: Rethinking ALK/IGF1R Translation
2026-08-18
AZD3463 offers translational researchers a dual-target framework for interrogating ALK and IGF1R signaling in neuroblastoma, including mutant ALK biology, PI3K/AKT/mTOR suppression, apoptosis, autophagy, and chemotherapy combinations. This article connects the compound’s experimental profile with biomarker strategy, pathway plasticity, and the limitations that must be addressed before clinical translation.
-
RNA Pol II Inhibition Triggers Active Apoptosis
2026-08-17
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program triggered by loss of hypophosphorylated RNA Pol IIA, rather than by transcriptional shutdown alone. The study identifies the Pol II degradation-dependent apoptotic response as a framework for interpreting drug-induced lethality in cancer research and for designing mechanistically resolved cell-death assays.
-
CHI3L1-IN-5: Astrocyte Assay Workflow
2026-08-17
CHI3L1-IN-5, also called Compound Z17, combines pathway-focused anti-inflammatory research with practical assays for astrocyte Aβ clearance and lysosomal recovery. This guide translates its reported properties into a controlled workflow, including dose-ranging, orthogonal readouts, handling guidance, and troubleshooting for neuroinflammation studies.
-
Neuroligin 1, D2-MSNs, and Repetitive Behavior
2026-08-16
The reference study identifies a cell-type-specific mechanism linking Neuroligin 1 loss to autistic-like repetitive behavior in mice: hyperactivation of striatal dopamine D2 receptor-expressing medium spiny neurons. By combining behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation, the authors implicate excessive protein kinase C signaling as a mechanistic contributor and define separable activity patterns for self-grooming and digging.
-
Ceftolozane/Tazobactam: Evidence and PK/PD
2026-08-15
The reference review establishes ceftolozane/tazobactam as an antipseudomonal cephalosporin/β-lactamase inhibitor combination with distinctive PBP binding, activity against selected resistant gram-negative organisms, and a clinically useful time-dependent PK/PD profile. Its synthesis of susceptibility, animal, pharmacokinetic, clinical, and safety evidence provides a framework for interpreting Ceftolozane MIC values and designing translational antibacterial studies.
-
SB 202190: Selective p38 MAP Kinase Inhibitor
2026-08-14
SB 202190 is a selective p38 MAP kinase inhibitor that targets p38α and p38β through ATP-site competition. Its defined biochemical potency, cell-permeable structure, and reported effects on inflammation, apoptosis, Raf–MEK–MAPK signaling, and memory-associated phenotypes make it a useful research tool, not a validated clinical therapy.
-
U0126-EtOH for Reliable Cell Assays
2026-08-14
Learn how U0126-EtOH (SKU A1337) can support interpretable cell viability, proliferation, cytotoxicity, and MAPK/ERK pathway experiments. This scenario-based guide covers mechanism, solvent handling, protocol design, data interpretation, and practical product-selection criteria.
-
RapaLink-1: Third-Generation mTOR Inhibitor Workflows
2026-08-13
RapaLink-1 combines bivalent mTOR engagement with practical workflows for glioma growth assays, resistance studies, and exploratory dormancy experiments. This guide connects quantified treatment conditions with assay design, formulation control, and troubleshooting for reproducible mTORC1 inhibition.
-
Neuroligin 1, D2-MSNs, and Repetitive Behavior
2026-08-13
This study identifies striatal dopamine D2 receptor-expressing medium spiny neurons (D2-MSNs) as a cell-type-specific circuit node linking Neuroligin 1 deficiency to autistic-like repetitive behaviors. By combining behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation, the authors implicate D2-MSN hyperactivation and PKC overactivity in excessive self-grooming and digging.
-
Torin2 and Mechanistic Cell-Death Assays
2026-08-12
Torin2 is a potent mTOR inhibitor for separating pathway suppression from genuine apoptotic commitment. This article connects Torin2 assay design with the 2025 discovery of Pol II degradation-dependent apoptosis, offering a more rigorous framework for cancer research.
-
CDK4/6–BET Inhibition in Pancreatic Cancer
2026-08-12
Gu et al. show that CDK4/6 inhibition can restrain pancreatic ductal adenocarcinoma growth while unintentionally enhancing invasive and epithelial-to-mesenchymal transition phenotypes. Their study identifies BET inhibition as a mechanistically complementary strategy that restores control of the GSK3β-mediated Wnt/β-catenin axis and produces stronger antitumor effects in vitro and in an orthotopic model.
-
Mubritinib (TAK 165): Reframing OXPHOS in AML
2026-08-11
Mubritinib (TAK 165) illustrates how a compound first associated with HER2 biology can be repositioned through metabolic dependency mapping. This thought-leadership article examines complex I inhibition, OXPHOS-dependent AML, translational assay design, cross-domain opportunities, and practical development strategy.
-
ABT-263 (Navitoclax): Practical Assay Guide
2026-08-11
ABT-263 (Navitoclax, SKU A3007) provides a controlled way to investigate Bcl-2 family-dependent apoptosis in cell and cancer biology workflows. This guide covers stock preparation, controls, assay design, and interpretation; it should not be used for diagnosis, treatment decisions, or clinical dosing.
-
U0126: MEK1/2 Inhibition for Reliable Assays
2026-08-10
U0126 (SKU BA2003) is a cell-permeable, non-ATP-competitive MEK1/2 inhibitor for dissecting MAPK/ERK signaling in viability, proliferation, cytotoxicity, and pathway studies. This scenario-based guide covers dose design, controls, storage, interpretation, and practical supplier-selection criteria for more defensible experiments.